Business
Shuttle Pharma FDA Orphan-Drug Nears Patient Enrollment Milestone for Phase 2 Clinical Trial
GAITHERSBURG, Md., May 08, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), announced today that it has nearly achieved 50% enrollment in the initial randomized portion of its Phase 2 clinical trial of Ropidoxuridine for the treatment of patients with glioblastoma, with treatmen
About this update from Shuttle Pharmaceuticals Holdings, Inc.
[{"type":"image","alt":"Shuttle Pharmaceuticals Holdings, Inc.","displaySize":"","headline":null,"caption":"Shuttle Pharmaceuticals Holdings, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":208,"url":"https://media.zenfs.com/en/globenewswire.com/17b6c8dccd5927138efbf7d9c8b1ea00"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/MdXxIvaxV5fqJqjQytSd2A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTI5MTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/17b6c8dccd5927138efbf7d9c8b1ea00","width":300,"height":208}},"lazy":false},{"type":"text","content":"GAITHERSBURG, Md., May 08, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), announced today that it has nearly achieved 50% enrollment in the initial randomized portion of its Phase 2 clinical trial of Ropidoxuridine for the treatment of patients with glioblastoma, with treatment sites reporting that the drug has been well tolerated and toxicity no greater than 2 on a scale of 1-5. Further, 84% of the enrolled patients have completed all seven cycles. Shuttle has begun analyzing pharmacokinetic/pharmacodynamic samples to compare the relationship between dose and response in terms of the extent and duration of Ropidoxuridine’s action. Our objective is to finalize enrollment later this year with follow up and data read out in 2026.","length":960,"tagName":"p"},{"type":"text","content":"“We are incredibly encouraged by the expedited progress of our Phase 2 trial and the dedication of our team, clinical partners, and patients who are making this milestone possible,” commented Shuttle Pharma's Chairman and Chief Scientific Officer, Anatoly Dritschilo, M.D. “If approved, we believe that Ropidoxuridine has the potential to redefine the standard approach for how to care for patients with glioblastoma.”","length":422,"tagName":"p"},{"type":"text","content":"Ropidoxuridine (IPdR) is Shuttle Pharma's lead candidate radiation sensitizer for use in combination with RT to treat brain tumors (glioblastoma), a deadly malignancy of the brain with no known cure. Shuttle Pharma previously received Orphan Drug Designation from the FDA, providing Shuttle Pharma with p...